Our research group specializes in personalized medicine, with a focus on drug stability in individualized preparations for oral and parenteral administration, population pharmacokinetic/pharmacodynamic models, and pharmacogenomics. We also conduct advanced interventions, including drug evaluation, effectiveness and safety studies, as well as mobile health and telepharmacy. In 2022, we collaborated with other groups on various eCOREs, published 25 articles publications in indexed journals and 4 in non-indexed journals, and worked on 15 different own projects, eight of which received grant funding. Our research has contributed to the study of biological medications and pharmacokinetic models for various drugs and pathologies. This year, we also studied health outcomes and medication use in COVID-19 patients and explored innovative projects such as 3D printing for personalized pediatric treatments and the optimization of fludarabine therapy before CAR-T cell administration.
eCOREs
